Clinical Trial Update: A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 crossover bioequivalence study comparing ATI-0918 and liposomal doxorubicin (DOXIL/CAELYX) in patients with ovarian cancer, sponsored by Azaya Therape…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Neoplasm of Female Reproductive System
• Ovarian Cancer
• Ovarian Epithelial Cancer

Drugs mentioned

• ATI-0918
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: Azaya Therapeutics, Inc. | Conditions: Ovarian Cancer, Malignant Female Reproductive System Neoplasm | Phase 1 | Status: UNKNOWN